StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.19+0.02 (+0.20%)

Close on Nov 18, 2026Market cap $857.19MP/E –Yield –

Corvus Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Corvus Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$45.23M. For fiscal 2025 it was -$32.97M. The highest annual figure on record is -$13.08M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.97M–
FY2023Dec 31, 2023-$23.97M–
FY2022Dec 31, 2022-$27.29M–
FY2021Dec 31, 2021-$36.72M–
FY2020Dec 31, 2020-$34.85M–
FY2019Dec 31, 2019-$37.35M–
FY2018Dec 31, 2018-$41.34M–
FY2017Dec 31, 2017-$46.48M–
FY2016Dec 31, 2016-$30.06M–
FY2015Dec 31, 2015-$13.08M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.98M–
Q1 FY2026Mar 31, 2026-$10.47M–
Q4 FY2025Dec 31, 2025-$9.22M–
Q3 FY2025Sep 30, 2025-$9.57M–
Q2 FY2025Jun 30, 2025-$5.89M–
Q1 FY2025Mar 31, 2025-$8.30M–
Q4 FY2023Dec 31, 2023-$5.17M–
Q3 FY2023Sep 30, 2023-$5.43M–
Q2 FY2023Jun 30, 2023-$5.22M–
Q1 FY2023Mar 31, 2023-$8.15M–
Q4 FY2022Dec 31, 2022-$7.55M–
Q3 FY2022Sep 30, 2022-$7.19M–
Q4 FY2020Dec 31, 2020-$8.21M–
Q4 FY2019Dec 31, 2019-$8.52M–
Q3 FY2019Sep 30, 2019-$10.61M–
Q2 FY2019Jun 30, 2019-$9.21M–
Q1 FY2019Mar 31, 2019-$9.01M–
Q4 FY2018Dec 31, 2018-$8.39M–
Q3 FY2018Sep 30, 2018-$10.96M–
Q2 FY2018Jun 30, 2018-$10.94M–
Q1 FY2018Mar 31, 2018-$11.05M–
Q4 FY2017Dec 31, 2017-$10.97M–
Q3 FY2017Sep 30, 2017-$10.82M–
Q2 FY2017Jun 30, 2017-$11.83M–
Q1 FY2017Mar 31, 2017-$12.86M–
Q4 FY2016Dec 31, 2016-$10.02M–
Q3 FY2016Sep 30, 2016-$6.78M–

More Corvus Pharmaceuticals figures

See a number that looks wrong?